Yannick Bulliard

Yannick Bulliard is a seasoned professional in the biopharmaceutical industry with extensive experience in program leadership and research, particularly in CAR-T and regulatory T cell-based therapies. Currently serving as a Senior Program Director at Tr1X since March 2024, Bulliard focuses on developing innovative treatments for autoimmune and inflammatory diseases. Prior roles include Senior Director of CAR-T Research at Appia Bio and Atara Biotherapeutics, where significant team expansions and the management of key oncology and autoimmunity projects were achieved. Experience also encompasses leadership positions at Immatics and Amgen, contributing to successful asset developments and overseeing substantial cross-functional teams. Educational credentials include a Ph.D. in Molecular Virology from EPFL and a Master's in Molecular Biology from the University of Fribourg, complemented by fellowships at notable institutions.